Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis

Published:2018-08-21 Issue:11 Volume:144 Page:2245-2261
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Kaufman Howard L.^ORCID,Schwartz Lawrence H.,William William N.,Sznol Mario,Fahrbach Kyle,Xu Yingxin,Masson Eric,Vergara-Silva Andrea

Funder

AstraZeneca

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-018-2738-x/fulltext.html

Reference57 articles.

1. AstraZeneca Pharmaceuticals LP (2017) Imfinzi™ (durvalumab) injection, for intravenous use [prescribing information]. AstraZeneca Pharmaceuticals LP, Wilmington

2. Bellmunt J et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026. https://doi.org/10.1056/NEJMoa1613683

3. Blumenthal GM et al (2017) Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis. JAMA Oncol 3:e171029. https://doi.org/10.1001/jamaoncol.2017.1029

4. Booth CM, Eisenhauer EA (2012) Progression-free survival: meaningful or simply measurable? J Clin Oncol 30:1030–1033. https://doi.org/10.1200/JCO.2011.38.7571

5. Borghaei H et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med 373:1627–1639. https://doi.org/10.1056/NEJMoa1507643

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group;Journal of Clinical Oncology;2023-12-10

2. Statistical considerations in long-term efficacy evaluation of anti-cancer therapies;Frontiers in Pharmacology;2023-10-03

3. Trial Design for Cancer Immunotherapy: A Methodological Toolkit;Cancers;2023-09-21

4. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis;JNCI: Journal of the National Cancer Institute;2023-08-04